1. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT and CT-guided fine-needle biopsy;DelMaschio, A.; Vanzulli, A.; Sironi, S.; Castrucci, M.; Mellone, R.; Staudacher, C.;Radiology,1991
2. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank;Ritts, R.E.; DelVillano, B.C.; Go, V.L.W.; Herberman, R.B.; Klug, T.L.; Zurawski, V.R.;IntJ Cancer,1984
3. Evaluation of a serological marker, CA 19-9, in the diagnosis of pancreatic cancer;Pleskow, D.K.; Berger, H.J.; Gyves, J.; Allen, E.; McLean, A.; Podolsky, D.K.;Ann Intern Med,1989
4. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases;Paganuzzi, M.; Onetto, M.; Marroni, P.; Barone, D.; Conio, M.; Aste, H.;Cancer,1988
5. CA 19-9 estimation in the assessment of pancreatic or biliary tract malignancy - what is the most efficient threshold value?;Welfare, M.; Tanner, A.;EurJr Gastroenterol Hepatol,1991